Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.
Stock data | 2023 | Change |
---|---|---|
Price | $13.56 | N/A |
Market Cap | $13.77B | N/A |
Shares Outstanding | 1.02B | -0.79% |
Employees | 23.03K | N/A |
Shareholder Equity | 196.88B | 3.33% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.70 | N/A |
P/S Ratio | 6.85 | N/A |
P/B Ratio | 0.07 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0013 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.01B | N/A |
Earnings | $249.21M | N/A |
EPS | 19.30 | N/A |
Earnings Yield | 1.42 | N/A |
Gross Margin | 0.6114 | N/A |
Operating Margin | 0.1692 | N/A |
Net income margin | 0.1239 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $3.07B | N/A |
Total Debt | $142.35M | N/A |
Cash on Hand | $143.74M | N/A |
Debt to Equity | 0.0037 | -32.82% |
Cash to Debt | $1.01 | 22.44% |
Current Ratio | $1.81 | 15.79% |